TABLE 3.
Associations of olanzapine daily dose with metabolic parameters
| Metabolic parameter change % | n | 5 mg olanzapine daily dose increase | High dose of olanzapine a | ||
|---|---|---|---|---|---|
| E (95% CI) | p‐value | E (95% CI) | p‐value | ||
| Systolic blood pressure (mmHg) | 55 | −1.1 (−2.0 to −0.01) | 0.03 | 0.1 (−1.9 to 2.1) | 0.92 |
| Diastolic blood pressure (mmHg) | 55 | −1.8 (−3.0 to −0.7) | 0.01 | −1.7 (−4.1 to 0.6) | 0.16 |
| Fasting plasma glucose (mmol/L) | 200 | 0.4 (0.1 to 0.6) | 0.01 | 1.8 (1.3 to 2.3) | <0.001 |
| Triglycerides (mmol/L) | 182 | 0.2 (−0.2 to 0.6) | 0.25 | 0.0 (−0.8 to 0.8) | 0.95 |
| Total cholesterol (mmol/L) | 209 | −0.1 (−0.2 to −0.01) | 0.03 | −0.1 (−0.3 to 0.1) | 0.33 |
| LDL cholesterol (mmol/L) | 175 | −0.1 (−0.4 to 0.2) | 0.50 | 0.3 (−0.5 to 1.0) | 0.49 |
| HDL cholesterol (mmol/L) | 205 | −0.2 (−0.3 to 0.0) | 0.01 | −0.4 (−0.6 to −0.1) | 0.01 |
Note: Significant p‐values are indicated in bold.
Abbreviations: CI, confidence interval; E, effect size; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein.
a
High‐dose defined as >10 mg/day. A 5‐mg increase of olanzapine doses would correspond to a decreased 1.1 and 1.8 mmHg of systolic and diastolic blood pressure, to an increased 0.4 mmol/L of fasting glucose and to a decreased 0.1 and 0.2 mmol/L of total and HDL cholesterol, respectively.